Orange Biomed Recognized for Breakthrough in Diabetes Management
Orange Biomed, the creator of an innovative pocket-sized A1C testing device, has recently received accolades for its cutting-edge microfluidic technology. This remarkable recognition places the company among the elite in the healthcare innovation sector, emphasizing its significant progress in enhancing accessibility and accuracy for chronic disease management.
Recognized as a Top Healthcare Innovator
The inclusion of Orange Biomed in a prestigious list showcasing healthcare innovations underscores the company's growing impact within the U.S. healthcare market. This recognition reflects the vital need for more accessible diabetes monitoring solutions and the promise of the OBM rapid A1C device to meet this demand.
An Innovative Solution for Diabetes Patients
The OBM rapid A1C represents a significant advancement, marking the first portable method for measuring glycated hemoglobin through microfluidic technology. Unlike traditional laboratory tests that may hinder patient accessibility, this device offers an easy alternative, especially for those facing barriers to regular medical check-ups.
Addressing Unmet Needs in Healthcare
A panel of U.S. medical experts and professionals recognized Orange Biomed for its efforts to tackle unmet needs within the healthcare system. The evaluators emphatically noted that the OBM rapid A1C could fundamentally change how diabetes patients monitor their health, eliminating logistical challenges and reducing costs typically associated with lab tests.
Community Engagement and Awareness Campaign
In addition to its groundbreaking product development, Orange Biomed is committed to expanding its impact through the "M.A.P. YOUR HEALTH" initiative. This campaign fosters collaboration with health organizations and community groups, emphasizing the importance of chronic disease prevention and access to necessary healthcare.
Vision for Future Innovation
CEO and co-president Yeaseul Park expressed pride in this honor, viewing it as validation of the company's promise to contribute positively to global healthcare. Park stated, "Being named to the Top 40 is more than an honor—it's proof that our technology can make a real impact in the U.S. healthcare system. Our focus is on building strong partnerships in the U.S. and turning these opportunities into real impact in the healthcare system." This reflects Orange Biomed’s commitment to driving healthcare advancements.
Strong Backing and Future Plans
With over USD 7.5 million in funding and multiple innovation accolades under its belt, Orange Biomed is positioned solidly within the healthcare landscape. The company has showcased its advancements at major U.S. forums like the American Diabetes Association's Innovation Hub and the Diabetes Technology Meeting (DTM), actively engaging with professional communities through associations such as ADLM and ADCES. Looking ahead, Orange Biomed is preparing a 510(k) submission to the FDA, aiming for potential clearance of its revolutionary product.
Frequently Asked Questions
What is Orange Biomed's flagship product?
The OBM rapid A1C is Orange Biomed's flagship product and is a portable device that measures glycated hemoglobin (A1C) utilizing microfluidic technology.
How does the OBM rapid A1C device improve diabetes monitoring?
This device enhances diabetes monitoring by providing a more accessible option compared to traditional lab testing, thereby addressing barriers to regular health checks.
What is the "M.A.P. YOUR HEALTH" initiative?
Orange Biomed's "M.A.P. YOUR HEALTH" campaign collaborates with community and health organizations to promote chronic disease prevention and improve access to healthcare.
Who recognized Orange Biomed as a top innovator?
A panel of U.S. medical experts recognized Orange Biomed for its innovative solutions and efforts to address unmet needs in the healthcare sector.
What future developments is Orange Biomed pursuing?
Orange Biomed is preparing a 510(k) submission to the FDA for its product, indicating its commitment to gaining approval for wider usage and distribution.
